Rifaximin in the management of hepatic encephalopathy;Rifaximin zur behandlung der hepatischen enzephalopathie

Journal fur Gastroenterologische und Hepatologische Erkrankungen

Volumn 8, Issue 3, 2010, Pages 32-35

  Fuhrmann, Valentin ^a   Wewalka, M ^a   Jager B ^a   Kitzberger, R ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Hepatic encephalopathy; Liver cirrhosis; Rifaximin

Indexed keywords

COLIMIDIN; LACTULOSE; METRONIDAZOLE; NEOMYCIN; PLACEBO; RIFAXIMIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; PATHOGENESIS; REVIEW;

EID: 77957819660     PISSN: 17286263     EISSN: 17286271     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Ferenci P. Hepatic encephalopathy. In: Haubrich W, Schaffner F, Berk JE (eds). Bockus Gastroenterology. WB Saunders, Philadelphia, 1995; 1998-2003.
2. th World Congress of Gastroenterology, Vienna 1998. Hepatology 2002; 35: 716-21.
3. Blei A, Cordoba J. Hepatic encephalopathy. Am J Gastroenterol 2001; 96: 1968-76.
4. Häussinger D, Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. Gut 2008; 57: 1156-65.
5. Ong JP, Aggarwal A, Krieger D, Easley KA, Karafa MT, Van Lente F, Arroliga AC, Mullen KD. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med 2003; 114: 188-93. (Pubitemid 36294003)
6. Norenberg M. Astrocytic-ammonia interactions in hepatic encephalopathy. Sem Liv Dis 1996; 16: 245-53.
7. Olde Damink SW, Deutz NE, Dejong CH, Soeters PB, Jalan R. Interorgan ammonia metabolism in liver failure. Neurochem Int 2002; 41: 177-88. (Pubitemid 34521691)
8. Gerber T, Schomerus H. Hepatic encephalopathy in liver cirrhosis: pathogenesis, diagnosis and management. Drugs 2000; 60: 1353-70. (Pubitemid 32039391)
9. Lighthouse J, Naito Y, Helmy A, Hotten P, Fuji H, Min CH, Yoshioka M, Marotta F. Endotoxinemia and benzodiazepine-like substances in compensated cirrhotic patients: a randomized study comparing the effect of rifaximine alone and in association with a symbiotic preparation. Hepatol Res 2004; 28: 155-60. (Pubitemid 38220225)
10. Blei A. Infection, inflammation and hepatic encephalopathy, synergism redefined. J Hepatol 2004; 40: 327-30. (Pubitemid 38115840)
11. Shawcross DL, Davies NA, Williams R, Jalan R. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammoniemia in cirrhosis. J Hepatol 2004; 40: 247-54. (Pubitemid 38115829)
12. Shawcross DL, Shabbir SS, Taylor NJ, Hughes RD. Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology 2010; 51: 1062-9.
13. AlSibae M, McGuire BM. Current trends in the treatment of hepatic encephalopathy. Ther Clin Risk Manag 2009; 5: 617-26.
14. Gebhardt R, Beckers G, Gaunitz F, Haupt W, Jonitza D, Klein S, Scheja L. Treatment of cirrhotic rats with L-ornithine-L-aspartate enhances urea synthesis and lowers serum ammonia levels. J Pharmacol Exp Ther 1997; 283: 1-6. (Pubitemid 27438939)
15. Kircheis G, Nilius R, Held C, Berndt H, Buchner M, Görtelmeyer R, Hendricks R, Krüger B, Kuklinski B, Meister H, Otto HJ, Rink C, Rösch W, Stauch S. Therapeutic effect of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1997; 25: 1351-60. (Pubitemid 27250753)
16. Acharya SK, Bhatia V, Sreenivas V, Khanal S, Panda SK. Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study. Gastroenterology 2009; 136: 2159-68.
17. Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 2009; 137: 885-91.
18. Mullen K, Sigal S, Sheikh M, Bass N, Poordad F, Merchant K, Huang S, Shaw A, Bortey E, Forbes W. Safety of rifaximin on patients with hepatic encephalopathy: results of a randomized, phase 3, placebo-controlled clinical trial. J Hepatol 2009; 50 (Suppl 1): S84-S85.
19. Williams R, James OF, Warnes TW, Morgan MY. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multicentre study. Eur J Gastroenterol Hepatol 2000; 12: 203-8. (Pubitemid 30166687)
20. Fachinformation Colidimin 200 mg Filmtabletten (Stand: April 2000).
21. Jiang Q, Jiang XH, Zheng MH, Jiang LM, Chen YP, Wang L. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encepahlopathy: a meta-analysis. Eur J Gastroenterol Hepatol 2008; 20: 1064-70.
22. Loguercio C, Federico A, De Girolamo V, Ferrieri A, Del Vecchio Blanco C. Cyclic treatment of chronic hepatic encephalopathy with rifaximin: results of a double-blind clinical study. Minerva Gastroenterol Dietol 2003; 49: 53-62. (Pubitemid 36505760)
23. Mas A, Rodés J, Sunyer L, Rodrigo L, Planas R, Vargas V, Castells L, Rodríguez-Martínez D, Fernández-Rodríguez C, Coll I, Pardo A; Spanish Association for the Study of the Liver Hepatic Encephalopathy Cooperative Group. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003; 38: 51-8.
24. Massa P, Vallerino E, Dodero M. Treatment of hepatic encephalopahty with rifaximin: double blind, double dummy study versus lactulose. Eur J Clin Res 1993; 4: 7-18. (Pubitemid 24090540)
25. Giacomo F, Francesco A, Michele N, Oronzo S, Antonella F. Rifaximin in the treatment of hepatic encephalopathy. Eur J Clin Res 1993; 4: 57-66.
26. Paik YH, Lee KS, Han KH, Song KH, Kim MH, Moon BS, Ahn SH, Lee SJ, Park HJ, Lee DK, Chon CY, Lee SI, Moon YM. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J 2005; 46: 399-407. (Pubitemid 40959882)
27. Pedretti G, Calzetti C, Missale G, Fiaccadori F. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhosis. A double-blind, randomized trial. Ital J Gastroenterol 1991; 23: 175-8.
28. Festi D, Mazzella G, Orsini M, Sottili S, Sangermano A, Li Bassi S, Parini P, Ferrieri A, Falcucci M, Grossi L, Marzio L, Roda E. Rifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safety. Curr Ther Res 1993; 54: 598-608.
29. Di Piazza S, Gabriella Filippazzo M, Valenza LM, Morello S, Pastore L, Conti A, Cottone S, Pagliaro L. Rifaximine versus neomycin in the treatment of portosystemic encephalopathy. Ital J Gastroenterol 1991; 23: 403-7.
30. Miglio F, Valpiani D, Rossellini SR, Ferrieri A. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial. Curr Med Res Opin 1997; 13: 593-601.
31. De Marco F, Santamaria Amato P, D'Arienzo A. Rifaximin in collateral treatment of portal-systemic encephalopathy: a preliminary report. Curr Ther Res 1984; 36: 668-74. (Pubitemid 15128056)
32. Testa R, Eftimiadi C, Sukkar GS, De Leo C, Rovida S, Schito GC, Celle G. A non-absorbable rifamycin for treatment of hepatic encephalopathy. Drugs Exp Clin Res 1985; 11: 387-92. (Pubitemid 15246073)
33. Parini P, Cipolla A, Ronchi M, Salzetta A, Mazzella G, Roda E. Effect of paromomycin in the treatment of portal-systemic encephalopathy. Curr Ther Res 1992; 52: 34-9.
34. Bass N, Mullen K, Sigal S, Sanyal A, Poordad F, Merchant K, Huang S, Shaw A, Bortey E, Forbes W. Rifaximin is effective in maintaining remission in hepatic encephalopathy: results of a large, randomized, placebo-controlled trial. J Hepatol 2009; 50 (Suppl 1): S39.
35. Huang E, Esrailian E, Spiegel B. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis. Aliment Pharmacol Ther 2007; 26: 1147-61. (Pubitemid 47480963)
36. Neff G, Leevy CB, Frederick T, Merchant K, Huang S, Shaw AL, Forbes WP. Rifaximin reduces the risk of hospitalizations in patients with previous episodes of hepatic encephalopathy: results from a phase 3 placebo-controlled trial. Gastroenterology 2009; 136 (Suppl 1): A-11-A-12.
37. Neff GW, Kemmer N, Zacharias VC, Kaiser T, Duncan C, McHenry R, Jonas M, Novick D, Williamson C, Hess K, Thomas M, Buell J. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Transpl Proc 2006; 38: 3552-5. (Pubitemid 44908490)